NetworkNewsBreaks – Lexaria Bioscience Corp. (CS

NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Positive Findings from Master Collaborative Research Agreement

Biotechnology company and global drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) recently announced the successful completion of its master collaborative research agreement with the National Research Council of Canada (“NRC”) focused on technical aspects of DehydraTECH(TM)’s drug-delivery processes (http://nnw.fm/4XWje). An article further discussing the company reads, “Lexaria also noted that the National Research Council of Canada study discovered the remarkable stability of DehydraTECH technology, even under highly acidic conditions. ‘Other formulation technologies by third parties that have not been tested for pH stability cannot be relied upon to deliver stable quantities of the API in question within an acidic beverage,’ the news release states. ‘Since mildly acidic formulas are used in the vast majority of beverages sold in North America today, pH stability testing is a necessary aspect of safely delivering cannabinoids within popular beverage formats, and Lexaria’s technology is now proven capable of doing so.’”

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer